CA
NVAX icon

Continuum Advisory’s Novavax NVAX Stock Holding History

Continuum Advisory’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-22,600
Closed -$23.2K – 478
2023
Q3 		$23.2K Hold
22,600
– – ﹤0.01% 446
2023
Q2 		$23.2K Hold
22,600
– – ﹤0.01% 445
2023
Q1 		$23.2K Hold
22,600
– – ﹤0.01% 421
2022
Q4 		$23.5K Sell
22,600
-125
-0.6% -$2.21K ﹤0.01% 409
2022
Q3 		$27K Hold
22,725
– – ﹤0.01% 400
2022
Q2 		$34K Hold
22,725
– – 0.01% 398
2022
Q1 		$33K Buy
22,725
+125
+0.6% +$11.1K 0.01% 370
2021
Q4 		$37K Sell
22,600
-10
-0% -$1.72K 0.01% 296
2021
Q3 		$45K Buy
+22,610
New +$4.98M 0.01% 286

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Continuum Advisory's NVAX Position: Q4 2023 in Review

Continuum Advisory sold out of Novavax (NVAX) in Q4 2023, closing a stake of 22,600 shares — an estimated $23.2K sold.

Continuum Advisory first reported a position in NVAX in Q3 2021 and held it in 9 quarters. The position peaked at $45K in Q3 2021. 199 funds tracked by Wall St. Rank hold NVAX as of Q4 2023.

  • Continuum Advisory reported no remaining Novavax position as of Q4 2023 after selling out during the quarter.
  • Continuum Advisory sold 22,600 Novavax shares in Q4 2023, an estimated $23.2K.
  • Continuum Advisory first reported a position in Novavax in Q3 2021 and held it in 9 quarters.
  • Continuum Advisory's Novavax position peaked at $45K in Q3 2021.
  • 199 funds tracked by Wall St. Rank held Novavax as of Q4 2023.

Based on Continuum Advisory's 13F filing for Q4 2023, filed 14 Feb 2024.